Ahead of HBI 2023 next month, we catch up with dentistry panelist Rahma Samow, EVP dental services organizations at Straumann Group, to find out more about her role and the trends surrounding oral health and their impact on enterprise DSOs globally.
We look at how to build a dynamic, low-cost outpatient chain which delivers high quality care and at the UK venous market more generally with Jason Powell, whose UK Vein Clinic Group looks set to grow revenue 50% in 2024, after doubling sales in 2023.
The AI revolution is coming for oncology, according to CEO Ralph Hefti who helms pan-European radiotherapy group Stingray Healthcare. We catch up with the HBI 2023 panelist to find out more.
As an aging population compounds Germany’s workforce crisis, the search for staff continues to expand outside Europe. With the government launching an initiative to attract skilled care workers from Brazil and beyond, HBI speaks to two market experts to find out more.
Emerging markets-focused PE health care firm TVM Capital Healthcare is opening a new office in Riyadh, Saudi Arabia, to assist the expansion of its portfolio companies in the country.
The BBC’s Panorama team has found that there are private ADHD clinics in the UK that are prescribing for ADHD based on just a short and, it says, unreliable online assessment.
Last month Berlin-based Dorea - a subgroup of European care homes Groupe Maisons de Famille - became the latest German nursing home operator to file for restructuring due to financial difficulties. As the number of companies financially struggling ramps up at an alarming rate and in quick succession, HBI speaks to two market experts to find out what’s going on.
Dussmann, the big European facilities management company which also owns Kursana, the fifth largest German nursing home group, saw revenue grow 20% to €2.8 billion in 2022. The company claimed that this was “almost exclusively organic.” But the Care & Kids division which is mainly Kursana didn’t grow at all. Is it a Cinderella?
Multinational listed labs group Synlab continues to grow its core operations as Covid testing winds down and it prepares to go private, with a healthy 10% organic revenue growth in Q1 2023.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.